Foundry Partners LLC Makes New $3.57 Million Investment in Envista Holdings Co. (NYSE:NVST)

Foundry Partners LLC bought a new position in shares of Envista Holdings Co. (NYSE:NVST) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 148,437 shares of the company’s stock, valued at approximately $3,571,000. Foundry Partners LLC owned approximately 0.09% of Envista as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Headinvest LLC purchased a new stake in Envista during the third quarter worth about $28,000. Fifth Third Bancorp boosted its stake in shares of Envista by 98.1% during the 4th quarter. Fifth Third Bancorp now owns 1,254 shares of the company’s stock worth $30,000 after acquiring an additional 621 shares in the last quarter. Itau Unibanco Holding S.A. acquired a new stake in shares of Envista in the 3rd quarter worth approximately $47,000. Signaturefd LLC increased its stake in Envista by 1,297.9% in the 4th quarter. Signaturefd LLC now owns 2,614 shares of the company’s stock valued at $63,000 after purchasing an additional 2,427 shares in the last quarter. Finally, Covestor Ltd increased its stake in Envista by 33.9% in the 3rd quarter. Covestor Ltd now owns 2,462 shares of the company’s stock valued at $69,000 after purchasing an additional 624 shares in the last quarter.

Envista Price Performance

Shares of NVST opened at $20.13 on Tuesday. Envista Holdings Co. has a fifty-two week low of $18.95 and a fifty-two week high of $39.28. The stock has a fifty day moving average of $21.12 and a two-hundred day moving average of $22.84. The company has a current ratio of 2.23, a quick ratio of 1.90 and a debt-to-equity ratio of 0.33.

Envista (NYSE:NVST) last released its earnings results on Wednesday, February 7th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.04). Envista had a negative net margin of 3.90% and a positive return on equity of 6.31%. The business had revenue of $645.60 million during the quarter, compared to analyst estimates of $638.37 million. The business’s revenue for the quarter was down 2.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 earnings per share. Equities research analysts forecast that Envista Holdings Co. will post 1.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

NVST has been the topic of several research reports. Leerink Partnrs reissued an “underperform” rating on shares of Envista in a report on Monday, February 26th. TheStreet downgraded shares of Envista from a “c” rating to a “d+” rating in a report on Wednesday, February 7th. SVB Leerink began coverage on shares of Envista in a report on Monday, February 26th. They issued an “underperform” rating and a $19.00 price target on the stock. William Blair cut shares of Envista from an “outperform” rating to a “market perform” rating in a research note on Thursday, February 8th. Finally, UBS Group assumed coverage on Envista in a research report on Friday, January 5th. They set a “neutral” rating and a $26.00 price objective for the company. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Envista currently has an average rating of “Hold” and an average price target of $29.60.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.